Cross-Sector entity
Bayer is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention Hope Medicine, all published on March 25, 2026.
2 verified stories tracked
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Bayer is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention Hope Medicine, all published on March 25, 2026. Each carries 3 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Hope Medicine. Shared-story counts are live from our verified record — not editorial picks.
Phase III Initiation
First patient dosed in the pivotal Phase III clinical trial for endometriosis.
Phase II Completion
Positive results from Phase II studies demonstrate pain reduction and safety.
Licensing Agreement
Hope Medicine acquires global rights for HMI-115 from Bayer.
Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.
Source: manilatimes.net · prnewswire.com
